Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder: a 16-week case series

Gino Pozzi, Luigi Janiri, Marco Di Nicola, Daniela Tedeschi, Giovanni Martinotti, Ofelia De Vita, Marisa Monetta

Research output: Contribution to journalArticle

16 Citations (Scopus)


Obsessive-compulsive disorder (OCD) is a relatively common, often chronic and disabling mental disorder associated to substantial impact on the quality of life.1 First-line treatments for OCD, cognitive behavioral therapy and selective serotonin reuptake inhibitors (SSRIs), produce significant improvement in only about 60% of patients. Moreover, many patients who are considered to be "responders" show significant residual symptoms and comorbidity.2 In cases of partial response to SSRIs, published expert guidelines recommend switching SSRIs and possibly augmenting with different medications, including atypical antipsychotic agents.3 Convergent evidence from genetic, neuroimaging, and open-label treatment studies supports a glutamatergic hyperactivity associated with OCD, which may represent the consequence of functional alterations of the glutamate transporter EAAC-1.4 Glutamate-modulating agents may therefore hold promise in treatment-refractory subjects.5 The new antiepileptic drug pregabalin (PGB) is a derivate of the inhibitory neurotransmitter [gamma]-aminobutyric acid; it modulates the synaptic release of glutamate and monoaminergic neurotransmitters via the [alpha]2d subunits of the voltage-gated Ca2+ channels and modulates the hippocampal theta oscillations.6 It has been shown to be particularly effective in several anxiety disorders, especially generalized anxiety disorder (GAD) and, to a lesser extent, social anxiety disorder and posttraumatic stress disorder, whereas few data are available on OCD.7,8 The aim of the present study was to assess the effectiveness of PGB augmentation in treatment-resistant OCD.
Original languageEnglish
Pages (from-to)675-677
Number of pages3
JournalJournal of Clinical Psychopharmacology
Publication statusPublished - 2011


  • Obsessive-Compulsive Disorder
  • Pregabalin


Dive into the research topics of 'Pregabalin augmentation in treatment-resistant obsessive-compulsive disorder: a 16-week case series'. Together they form a unique fingerprint.

Cite this